Yervoy

(Ipilimumab)

Phase 3Monoclonal antibody

Ipilimumab is used to treat certain types of cancer, including melanoma and other cancers, by helping the immune system recognize and attack cancer cells.[1] Yervoy is currently being investigated across 137 indications[3], with its most advanced program in Phase 3.[1]

Yervoy is one of 1744 biologic programs targeting Glioma. It is currently in Phase 3.

137

Indications

700

Total Trials

Active Trials

1,743

Competitors

FDA Application

NDA/BLA/ANDA regulatory filings

Pipeline

Status by Indication[3][1]

Indication

GliomaActive, not recruiting

Head and Neck CarcinomaActive, not recruiting

HIV InfectionActive, not recruiting

Gastroesophageal Junction AdenocarcinomaActive, not recruiting

Colorectal CarcinomaUnknown

Nerve Sheath NeoplasmActive, not recruiting

Uterine LeiomyosarcomaActive, not recruiting

MetastasisActive, not recruiting

Merkel Cell Skin CancerActive, not recruiting

Prostate AdenocarcinomaActive, not recruiting

GliomaPhase 2

Active, not recruiting

Head and Neck CarcinomaPhase 1/Phase 2

Active, not recruiting

HIV InfectionPhase 1

Active, not recruiting

Gastroesophageal Junction AdenocarcinomaPhase 2

Active, not recruiting

Colorectal CarcinomaPreclinical

Unknown

Nerve Sheath NeoplasmPhase 1

Active, not recruiting

Uterine LeiomyosarcomaPhase 2

Active, not recruiting

MetastasisPhase 3

Active, not recruiting

Merkel Cell Skin CancerPhase 2

Active, not recruiting

Prostate AdenocarcinomaPhase 2

Active, not recruiting

Showing 10 of 137 indications

Competition

Competitive Landscape

2828 competitors in Breast Cancer

#DrugCompanyPhaseTrials

Yervoy

Bristol-Myers Squibb

Phase 3

13 2

Tecentriq

Roche

Preclinical

36 3

Halaven

Eisai

Preclinical

38 4

Avastin

MS Contin

2 6

Zolymbus

AbbVie

Preclinical

1 7

Blenoxane

Bristol-Myers Squibb

Preclinical

1 8

Voltaren

Novartis

Preclinical

1 9

Effexor

WWyeth-Lederle Vaccines

Preclinical

2 10

Acupan

YYonsei University

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2026

Phase 1Active, not recruiting

Leukemia

NCT02879695

Phase 1Active, not recruiting

Myelodysplastic Syndrome

NCT02890329

Phase 1Active, not recruiting

Renal Cell Carcinoma

NCT04495257

Phase 1/2Active, not recruiting

Prostate Cancer

NCT01688492

Phase 2Active, not recruiting

Merkel Cell Carcinoma

NCT03071406

Phase 1Active, not recruiting

Metastatic

NCT02496208

Clinical

Trials by Indication[1]

Melanoma31 trials

Ipilimumab With or Without Dabrafenib, Trametinib, and/or Nivolumab in Treating Patients With Melanoma That Is Metastatic or Cannot Be Removed by Surgery

Terminated·NNational Cancer Institute (NCI)·Phase 1·NCT01940809·15 enrolled

Immunogenicity and Biomarker Analysis of Neoadjuvant Ipilimumab for Melanoma

Completed·DDiwakar Davar·Phase 1·NCT00972933·59 enrolled

Dacarbazine and Ipilimumab vs. Dacarbazine With Placebo in Untreated Unresectable Stage III or IV Melanoma

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 3·NCT00324155·681 enrolled

Show 28 more trials

An Investigational Immuno-therapy Study of Nivolumab Combined With Ipilimumab Compared to Nivolumab by Itself After Complete Surgical Removal of Stage IIIb/c/d or Stage IV Melanoma

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 3·NCT03068455·1,844 enrolled

Safety and Efficacy Study of BMS-908662 in Combination With Ipilimumab in Subjects With Advanced Melanoma

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 1·NCT01245556·8 enrolled

Monoclonal Antibody Therapy and Vaccine Therapy in Treating Patients With Resected Stage III or Stage IV Melanoma

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 2·NCT00084656·77 enrolled

Ipilimumab and Dabrafenib in the 1st Line Tx of Unresectable Stage III/IV Melanoma

Terminated·UUniversity of Utah·Phase 1·NCT02200562·6 enrolled

Addition of Ipilimumab (MDX-010) To Isolated Limb Infusion (ILI) With Standard Melphalan and Dactinomycin In The Treatment of Advanced Unresectable Melanoma of The Extremity

Completed·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT01323517·26 enrolled

Radiation and Combination Immunotherapy for Melanoma

Completed·MMasonic Cancer Center, University of Minnesota·Phase 2·NCT03850691·4 enrolled

Retrospective Assessment of Adverse Events-related Healthcare Resource Utilization and Costs of Immune Checkpoint Inhibitor and Targeted Therapy for Adjuvant Treatment of Melanoma

Completed· Novartis logo

Novartis··NCT05714371·618 enrolled

A Study of NIVO Plus IPI and Guadecitabine or NIVO Plus IPI in Melanoma and NSCLC Resistant to Anti-PD1/PDL1

Unknown status·IItalian Network for Tumor Biotherapy Foundation·Phase 2·NCT04250246·184 enrolled

Multicenter Phase 1b Trial Testing the Neoadjuvant Combination of Domatinostat, Nivolumab and Ipilimumab in IFN-gamma Signature-low and IFN-gamma Signature-high RECIST 1.1-measurable Stage III Cutaneous or Unknown Primary Melanoma

Completed·TThe Netherlands Cancer Institute·Phase 1/2·NCT04133948·44 enrolled

A Safety and Efficacy Study of Multiple Administration Regimens for Nivolumab Plus Ipilimumab in Subjects With Melanoma

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 3·NCT02905266·106 enrolled

Assessing the Tolerance and Clinical Benefit of feCAl tranSplantation in patientS With melanOma

Completed·AAssistance Publique - Hôpitaux de Paris·Phase 2·NCT04988841·70 enrolled

Safety and Efficacy in Participants With Metastatic BRAF-mutant Melanoma Treated With Encorafenib With and Without Binimetinib in Combination With Nivolumab and Low-dose Ipilimuma

Terminated·JJason J. Luke, MD·Phase 1/2·NCT04655157·2 enrolled

Study of Combination of Ipilimumab and Nivolumab in Patients With Melanoma

Completed·NNYU Langone Health·Phase 2·NCT02970981·18 enrolled

Stereotactic Radiosurgery and Immune Checkpoint Inhibitors With NovoTTF-200M for the Treatment of Melanoma Brain Metastases

Active, not recruiting·EEmory University·Phase 1·NCT05341349·1 enrolled

An Investigational Immuno-therapy Study to Evaluate Safety and Effectiveness in Patients With Melanoma That Has Spread to the Brain, Treated With Nivolumab in Combination With Ipilimumab, Followed by Nivolumab by Itself

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 2·NCT02320058·119 enrolled

Phase I of Histone Deacetylase (HDAC) Inhibitor Panobinostat With Ipilimumab With Unresectable III/IV Melanoma

Completed·HH. Lee Moffitt Cancer Center and Research Institute·Phase 1·NCT02032810·17 enrolled

Intratumoral CAVATAK (CVA21) and Ipilimumab in Patients With Advanced Melanoma (VLA-013 MITCI)

Completed·VViralytics·Phase 1·NCT02307149·50 enrolled

PH 1 Biomarker Study of Nivolumab and Ipilimumab and Nivolumab in Combination With Ipilimumab in Advanced Melanoma

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 1·NCT01621490·170 enrolled

VX15/2503 With or Without Ipilimumab and/or Nivolumab in Patients With Resectable Stage IIIB-D Melanoma

Active, not recruiting·EEmory University·Phase 1·NCT03769155·41 enrolled

Study to Evaluate the Safety and Efficacy of Two Different Dosing Schedules of Pembrolizumab (MK-3475) Compared to Ipilimumab in Participants With Advanced Melanoma (MK-3475-006/KEYNOTE-006)

Completed· Merck & Co. logo

Merck & Co.·Phase 3·NCT01866319·834 enrolled

Vaccine Combining Multiple Class I Peptides and Montanide ISA 51VG With Escalating Doses of Anti-PD-1 Antibody Nivolumab or Ipilimumab With Nivolumab For Patients With Resected Stages IIIC/ IV Melanoma

Completed·HH. Lee Moffitt Cancer Center and Research Institute·Phase 1·NCT01176474·73 enrolled

Phase II Trial of Stereotactic Body Radiotherapy Followed by Ipilimumab in Treating Patients With Stage IV Melanoma

Terminated·UUniversity of Washington·Phase 2·NCT01970527·23 enrolled

Neoadjuvant and Adjuvant Anti-PD1 or Combinations for Locoregionally Advanced Melanoma

Recruiting·HH. Lee Moffitt Cancer Center and Research Institute·Phase 2·NCT06295159·90 enrolled

Anti-SEMA4D Monoclonal Antibody VX15/2503 With Nivolumab or Ipilimumab in Treating Patients With Stage III or IV Melanoma

Terminated·JJonsson Comprehensive Cancer Center·Phase 1·NCT03425461·6 enrolled

Axitinib + Ipilimumab in Advanced Melanoma

Recruiting·HH. Lee Moffitt Cancer Center and Research Institute·Phase 2·NCT04996823·25 enrolled

Evaluation of Safety and Efficacy of Patients With Four and More Symptomatic Brain Metastases of Melanoma

Terminated·UUniversity Hospital Tuebingen·Phase 2·NCT03728465·6 enrolled

A Study of Tilsotolimod in Combo With Ipilimumab vs Ipilimumab Alone in Subjects With Anti-PD-1 Refractory Melanoma

Terminated·IIdera Pharmaceuticals, Inc.·Phase 3·NCT03445533·481 enrolled

Trial of Neoadjuvant Ipilimumab Followed by Melphalan Via Isolated Limb Infusion for Patients With Unresectable In-transit Extremity Melanoma

Completed·—·Phase 1·NCT02115243·4 enrolled

Metastatic Melanoma17 trials

Expanded Access Program With Nivolumab in Combination With Ipilimumab in Patients With Tumors Unable to be Removed by Surgery or Metastatic Melanoma

No longer available· Bristol-Myers Squibb logo

Bristol-Myers Squibb··NCT02186249

Immunotherapy Efficacy and PD-L1 as a Predictive Biomarker in Metastatic Melanoma in Slovenia

Recruiting·IInstitute of Oncology Ljubljana·N/A·NCT07422779·100 enrolled

Phase I/IIa Dose Finding Study of Triplet Regimen of Relatlimab Ipilimumab and NIvolumab in First Line Therapy of Metastatic Melanoma (TRINITY)

Not yet recruiting·MM.D. Anderson Cancer Center·Phase 1/2·NCT06683755·30 enrolled

Show 14 more trials

Study of Nivolumab Given Sequentially With Ipilimumab in Subjects With Advanced or Metastatic Melanoma (CheckMate 064)

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 2·NCT01783938·138 enrolled

IFN-Gamma Expression as a Predictor of Response to Immune Checkpoint Inhibitors in First-Line Metastatic Melanoma

Completed·IInstitute of Oncology Ljubljana·N/A·NCT07436390·132 enrolled

Clinical Evaluation of Yervoy in Combination With Adoptive T Cell Transfer for Metastatic Melanoma Patients

Terminated·SSheba Medical Center·Phase 2·NCT01988077·2 enrolled

A Trial Evaluating the Safety & Efficacy of Intra-Tumoral Ipilimumab in Combination With Intra-venous Nivolumab in Patients With Metastatic Melanoma

Completed·GGustave Roussy, Cancer Campus, Grand Paris·Phase 1/2·NCT02857569·90 enrolled

A Study of Two Different Dose Combinations of Nivolumab in Combination With Ipilimumab in Subjects With Previously Untreated, Unresectable or Metastatic Melanoma

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 3·NCT02714218·387 enrolled

A Combination of Ipilimumab and Fotemustine for Treat Unresectable Locally Advanced or Metastatic Melanoma

Completed·IItalian Network for Tumor Biotherapy·Phase 2·NCT01654692·86 enrolled

Ipilimumab + Temozolomide in Metastatic Melanoma

Completed·MM.D. Anderson Cancer Center·Phase 2·NCT01119508·64 enrolled

A Phase 2 Study to Assess the Safety and Efficacy of IMO-2125 With 8 mg Ipilimumab in Patients With Metastatic Melanoma

Completed·IIdera Pharmaceuticals, Inc.·Phase 2·NCT02644967·53 enrolled

NY-ESO-1 Vaccine in Combination With Ipilimumab in Patients With Unresectable or Metastatic Melanoma

Terminated·LLudwig Institute for Cancer Research·Phase 1·NCT01810016·8 enrolled

Ipilumumab and Nivolumab With or Without Hypofractionated Radiotherapy in Patients With Metastatic Melanoma

Recruiting·—·Phase 2·NCT03646617·54 enrolled

Trial of SBRT With Concurrent Ipilimumab in Metastatic Melanoma

Completed·RRadiotherapie·Phase 1·NCT02406183·13 enrolled

Monoclonal Antibody Therapy and Interleukin-2 in Treating Patients With Metastatic Melanoma

Completed·NNational Cancer Institute (NCI)·Phase 1/2·NCT00058279

Galectin Inhibitor (GR-MD-02) and Ipilimumab in Patients With Metastatic Melanoma

Completed·PProvidence Health & Services·Phase 1·NCT02117362·8 enrolled

Phase 3 Trial in Subjects With Metastatic Melanoma Comparing 3 mg/kg Ipilimumab Versus 10 mg/kg Ipilimumab

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 3·NCT01515189·831 enrolled

Non-Small Cell Lung Cancer7 trials

Study of Nivolumab (BMS-936558) in Combination With Gemcitabine/Cisplatin, Pemetrexed/Cisplatin, Carboplatin/Paclitaxel, Bevacizumab Maintenance, Erlotinib, Ipilimumab or as Monotherapy in Subjects With Stage IIIB/IV Non-small Cell Lung Cancer (NSCLC) (CheckMate 012)

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 1·NCT01454102·472 enrolled

Study of Pembrolizumab (MK-3475) Monotherapy in Advanced Solid Tumors and Pembrolizumab Combination Therapy in Advanced Non-small Cell Lung Cancer/ Extensive-disease Small Cell Lung Cancer (MK-3475-011/KEYNOTE-011)

Completed· Merck & Co. logo

Merck & Co.·Phase 1·NCT01840579·57 enrolled

An Investigational Immuno-therapy Trial of Nivolumab, or Nivolumab Plus Ipilimumab, or Nivolumab Plus Platinum-doublet Chemotherapy, Compared to Platinum Doublet Chemotherapy in Patients With Stage IV Non-Small Cell Lung Cancer (NSCLC)

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 3·NCT02477826·2,747 enrolled

Show 4 more trials

A Clinical Study Evaluating Nivolumab-containing Treatments in Patients With Advanced Non-small Cell Lung Cancer After Failing Previous PD-1/(L)1 Therapy and Chemotherapy

Withdrawn· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 1/2·NCT04151563

An Investigational Immuno-therapy Study to Test Combination Treatments in Patients With Advanced Non-Small Cell Lung Cancer

Terminated· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 2·NCT02750514·295 enrolled

Unresectable Stage IIIA/IIIB Non-small Cell Lung Cancer (NSCLC)

Completed·—·Phase 2·NCT03285321·105 enrolled

A Study to Assess BMS-986207 in Combination With Nivolumab and Ipilimumab as First-line Treatment for Participants With Stage IV Non-Small Cell Lung Cancer

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 2·NCT05005273·1 enrolled

Immunotherapy6 trials

A Study of Several Radiation Doses for Patients With Progression on Immunotherapy/Checkpoint Inhibitors

Active, not recruiting·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT03693014·69 enrolled

PHP and Immunotherapy in Metastasized UM

Active, not recruiting·LLeiden University Medical Center·Phase 1/2·NCT04283890·83 enrolled

The Rome Trial From Histology to Target: the Road to Personalize Target Therapy and Immunotherapy

Unknown status·FFondazione per la Medicina Personalizzata·Phase 2·NCT04591431·400 enrolled

Show 3 more trials

A Study to Evaluate Adaptive Dosing of Ipilimumab and Nivolumab Combination Immunotherapy

Active, not recruiting·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT03122522·70 enrolled

Immunotherapy in Patients With Early dMMR Rectal Cancer

Recruiting·OOdense University Hospital·Phase 2·NCT05732389·39 enrolled

An Investigational Immunotherapy Study of BMS-986299 Alone and in Combination With Nivolumab and Ipilimumab in Participants With Solid Cancers That Have Spread or Cannot be Removed

Terminated· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 1·NCT03444753·82 enrolled

Renal Cell Carcinoma5 trials

A Study of APX005M in Combination With Nivolumab and Ipilimumab in Treatment Naïve Patients With Advanced Melanoma or Renal Cell Carcinoma (RCC)

Active, not recruiting·YYale University·Phase 1·NCT04495257·26 enrolled

Study of Front Line Therapy With Nivolumab and Salvage Nivolumab + Ipilimumab in Patients With Advanced Renal Cell Carcinoma

Completed·MMichael B. Atkins, MD·Phase 2·NCT03117309·164 enrolled

A Phase II Study of Nivolumab With Ipilimumab and Cabozantinib in Patients With Untreated Renal Cell Carcinoma Brain Metastases

Recruiting·MM.D. Anderson Cancer Center·Phase 2·NCT05048212·20 enrolled

Show 2 more trials

Phase II Sequential Treatment Trial of Single Agent Nivolumab, Then Combination Ipilimumab + Nivolumab in Metastatic or Unresectable Non-Clear Cell Renal Cell Carcinoma (ANZUP1602)

Unknown status·AAustralian and New Zealand Urogenital and Prostate Cancer Trials Group·Phase 2·NCT03177239·85 enrolled

Nivolumab and Ipilimumab in T1aN0M0 Renal Cell Carcinoma Patients Ineligible for Surgical Treatment.

Unknown status·KKidney Cancer Research Bureau·Phase 2·NCT04134182·8 enrolled

88 more indications

Pancreatic Cancer5 trials

Nivolumab and Ipilimumab and Radiation Therapy in MSS and MSI High Colorectal and Pancreatic Cancer

Active, not recruiting·MMassachusetts General Hospital·Phase 2·NCT03104439·84 enrolled

Ipilimumab +/- Vaccine Therapy in Treating Patients With Locally Advanced, Unresectable or Metastatic Pancreatic Cancer

Completed·SSidney Kimmel Comprehensive Cancer Center at Johns Hopkins·Phase 1·NCT00836407·30 enrolled

Pooled Mutant KRAS-Targeted Long Peptide Vaccine Combined With Nivolumab and Ipilimumab for Patients With Resected Mismatch Repair Protein (MMR-p) Colorectal and Pancreatic Cancer

Active, not recruiting·SSidney Kimmel Comprehensive Cancer Center at Johns Hopkins·Phase 1·NCT04117087·27 enrolled

Show 2 more trials

Nivolumab, Ipilimumab and Chemoradiation in Pancreatic Cancer.

Completed·HHerlev Hospital·Phase 1/2·NCT04247165·55 enrolled

Ipilimumab, Nivolumab, Tocilizumab and Radiation in Pretreated Patients With Advanced Pancreatic Cancer

Terminated·HHerlev Hospital·Phase 2·NCT04258150·26 enrolled

Prostate Cancer5 trials

A Trial of Immunotherapy Strategies in Metastatic Hormone-sensitive Prostate Cancer

Unknown status·SSpanish Oncology Genito-Urinary Group·Phase 2/3·NCT03879122·135 enrolled

Neoadjuvant Lu-PSMA Radioligand Therapy and Ipilimumab in Men With Very High-risk Prostate Cancer

Terminated·UUniversity Hospital, Essen·Phase 1/2·NCT06388369·1 enrolled

T-Cell Responses to Neoantigens Post Treatment With Ipilimumab in Men With Metastatic Castration-Resistant Prostate Cancer

Completed·MM.D. Anderson Cancer Center·Phase 1·NCT02113657·30 enrolled

Show 2 more trials

A Study of Nivolumab Plus Ipilimumab, Ipilimumab Alone, or Cabazitaxel in Men With Metastatic Castration-Resistant Prostate Cancer (CheckMate 650)

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 2·NCT02985957·351 enrolled

Combining Ipilimumab With Abiraterone Acetate Plus Prednisone in Chemotherapy and Immunotherapy-naïve Patients With Progressive Metastatic Castration-resistant Prostate Cancer

Active, not recruiting·MMemorial Sloan Kettering Cancer Center·Phase 1/2·NCT01688492·54 enrolled

Glioblastoma5 trials

Association of Peripheral Blood Immunologic Response to Therapeutic Response to Adjuvant Treatment With Immune Checkpoint Inhibition (ICI) in Patients With Newly Diagnosed Glioblastoma or Gliosarcoma

Active, not recruiting·NNational Cancer Institute (NCI)·Phase 2·NCT04817254·47 enrolled

Trial of Combination Tumor Treating Fields (TTF; Optune), Nivolumab Plus/Minus Ipilimumab for Recurrent Glioblastoma

Terminated·BBaptist Health South Florida·Phase 2·NCT03430791·5 enrolled

A Trial of Neoadjuvant Therapy in Patients With Newly Diagnosed Glioblastoma

Terminated·UUniversity College, London·Phase 2·NCT05074992·1 enrolled

Show 2 more trials

An Expanded Access Program of Ipilimumab for Patients With Glioblastomas and Gliomas

No longer available·CCenter Trials & Treatment··NCT03460782

Nivolumab, Ipilimumab, and Short-course Radiotherapy in Adults With Newly Diagnosed, MGMT Unmethylated Glioblastoma

Completed·NNYU Langone Health·Phase 2·NCT03367715·10 enrolled

Lymphoma5 trials

CD19 Chimeric Receptor Expressing T Lymphocytes In B-Cell Non Hodgkin's Lymphoma, ALL & CLL

Active, not recruiting·—·Phase 1·NCT00586391·14 enrolled

MDX-010 in Treating Patients With Recurrent or Refractory Lymphoma

Terminated·NNational Cancer Institute (NCI)·Phase 1/2·NCT00089076·18 enrolled

Monoclonal Antibody Therapy in Treating Patients With Lymphoma or Colon Cancer That Has Not Responded to Vaccine Therapy

Completed·NNational Institutes of Health Clinical Center (CC)·Phase 1·NCT00047164·89 enrolled

Show 2 more trials

Nivolumab and Ipilimumab in Treating Patients With HIV Associated Relapsed or Refractory Classical Hodgkin Lymphoma or Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery

Terminated·NNational Cancer Institute (NCI)·Phase 1·NCT02408861·79 enrolled

PROCLAIM-CX-072: A Trial to Find Safe and Active Doses of an Investigational Drug CX-072 for Patients With Solid Tumors or Lymphomas

Terminated·CCytomX Therapeutics·Phase 1/2·NCT03013491·196 enrolled

Gastric Cancer4 trials

Nivolumab, Ipilimumab and Chemoradiation in Treating Patients With Resectable Gastric Cancer

Active, not recruiting·MM.D. Anderson Cancer Center·Phase 2·NCT03776487·32 enrolled

A Study to Test Combination Treatments in Participants With Advanced Gastric Cancer

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 2·NCT02935634·190 enrolled

Modified FOLFOX Plus/Minus Nivolumab and Ipilimumab vs. FLOT Plus Nivolumab in Patients With Previously Untreated Advanced or Metastatic Gastric Cancer

Completed·IInstitut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest·Phase 2·NCT03647969·262 enrolled

Show 1 more trial

Combination of Nivolumab and Ipilimumab in Breast, Ovarian and Gastric Cancer Patients

Terminated·EExcellaBio LLC·Phase 2·NCT03342417·5 enrolled

Nivolumab4 trials

Selective HDAC6 Inhibitor ACY-241 in Combination With Ipilimumab and Nivolumab

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 1·NCT02935790·1 enrolled

CD24Fc With Ipilimumab and Nivolumab to Decrease irAE (CINDI)

Withdrawn· Merck & Co. logo

Merck & Co.·Phase 1/2·NCT04060407

Nivolumab/Ipilimumab-Primed Immunotransplant for DLBCL

Completed·IIcahn School of Medicine at Mount Sinai·Phase 1·NCT03305445·6 enrolled

Show 1 more trial

Nivolumab Combined With Ipilimumab for Patients With Advanced Rare Genitourinary Tumors

Active, not recruiting·—·Phase 2·NCT03333616·100 enrolled

Metastatic Colorectal Cancer4 trials

iRECIST Evaluation's Relevance for DCR in MMR/MSI Metastatic Colorectal Cancer Patients on Nivolumab and Ipilimumab

Active, not recruiting·GGERCOR - Multidisciplinary Oncology Cooperative Group·Phase 2·NCT03350126·57 enrolled

NIVOLUMAB Plus IPILIMUMAB and TEMOZOLOMIDE in Microsatellite Stable, MGMT Silenced Metastatic Colorectal Cancer

Completed·FFondazione IRCCS Istituto Nazionale dei Tumori, Milano·Phase 2·NCT03832621·135 enrolled

A Study of a Patient-Specific Neoantigen Vaccine in Combination With Immune Checkpoint Blockade for Patients With Metastatic Colorectal Cancer

Active, not recruiting·SSeattle Project Corporation·Phase 2/3·NCT05141721·700 enrolled

Show 1 more trial

Regorafenib, Ipilimumab and Nivolumab for the Treatment of Chemotherapy Resistant Microsatellite Stable Metastatic Colorectal Cancer

Completed·—·Phase 1·NCT04362839·39 enrolled

Small Cell Lung Cancer3 trials

A Study of Rovalpituzumab Tesirine Administered in Combination With Nivolumab and With or Without Ipilimumab for Adults With Extensive-Stage Small Cell Lung Cancer

Terminated· AbbVie logo

AbbVie·Phase 1/2·NCT03026166·42 enrolled

Phase 3 Trial in Squamous Non Small Cell Lung Cancer Subjects Comparing Ipilimumab Plus Paclitaxel and Carboplatin Versus Placebo Plus Paclitaxel and Carboplatin

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 3·NCT02279732·342 enrolled

An Investigational Immuno-therapy Study of Nivolumab, or Nivolumab in Combination With Ipilimumab, or Placebo in Patients With Extensive-Stage Disease Small Cell Lung Cancer (ED-SCLC) After Completion of Platinum-based Chemotherapy

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 3·NCT02538666·907 enrolled

Hepatocellular Carcinoma3 trials

TACE or Ablation Combined With Sintilimab and Ipilimumab N01 as Neoadjuvant Therapy for Resectable Hepatocellular Carcinoma With Intermediate-High Recurrence Risk

Not yet recruiting·SSun Yat-sen University·Phase 2·NCT07487662·90 enrolled

Neoadjuvant Intra-tumor Double Immunotherapy for Hepatocellular Carcinoma.

Recruiting·SSecond Affiliated Hospital of Guangzhou Medical University·Phase 2·NCT06492408·90 enrolled

Different First-line Immunotherapy for Advancer Hepatocellular Carcinoma: A Prospective Observational Study on Efficacy and Immune Microenvironment

Not yet recruiting·FFudan University··NCT07147101·150 enrolled

Advanced Solid Tumors3 trials

Triplex Checkpoint Inhibitors Therapy for Advanced Solid Tumors

Recruiting·SSecond Affiliated Hospital of Guangzhou Medical University·Phase 1/2·NCT05187338·100 enrolled

A Study of BMS-986207 Given Alone and in Combination With Nivolumab or With Nivolumab and Ipilimumab in Advanced Solid Tumors

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 1/2·NCT02913313·101 enrolled

First-In-Human Study of Monoclonal Antibody BMS-986218 by Itself and in Combination With Nivolumab in Participants With Advanced Solid Tumors

Terminated· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 1/2·NCT03110107·376 enrolled

Kidney Cancer3 trials

SBRT With Combination Ipilimumab/Nivolumab for Metastatic Kidney Cancer

Active, not recruiting·OOntario Clinical Oncology Group (OCOG)·Phase 2·NCT04090710·66 enrolled

A Study to Evaluate the Safety and Efficacy of Nivolumab With Ipilimumab in Participants With Untreated Advanced Kidney Cancer Conducted in India

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 4·NCT04513522·101 enrolled

A BIOmarker Driven Trial With Nivolumab and Ipilimumab or VEGFR tKi in Naïve Metastatic Kidney Cancer

Completed·AAssociation Pour La Recherche des Thérapeutiques Innovantes en Cancérologie·Phase 2·NCT02960906·200 enrolled

Merkel Cell Carcinoma2 trials

Randomized Study of Nivolumab+Ipilimumab+/- SBRT for Metastatic Merkel Cell Carcinoma

Active, not recruiting·HH. Lee Moffitt Cancer Center and Research Institute·Phase 2·NCT03071406·50 enrolled

Study of the Drug Ipilimumab for Metastatic Merkel Cell Carcinoma

Withdrawn·NNational Cancer Institute (NCI)·Phase 2·NCT01913691

Patients With Solid Tumors2 trials

An Adaptive Study to Match Patients With Solid Tumors to Various Immunotherapy Combinations Based Upon a Broad Biomarker Assessment

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 1·NCT03335540·20 enrolled

Sargramostim With Ipilimumab Containing Therapy in Patients With Solid Tumors

Withdrawn·PPartner Therapeutics, Inc.·Phase 2·NCT05284214

Metastatic2 trials

Cabozantinib S-malate and Nivolumab With or Without Ipilimumab in Treating Patients With Metastatic Genitourinary Tumors

Active, not recruiting·NNational Cancer Institute (NCI)·Phase 1·NCT02496208·152 enrolled

Evaluating Safety & Efficacy Belinostat Combo w Nivo Alone & w Ipi in Patients w Treated Metastatic/Advanced Carcinomas w ARID1A Lof Mutation

Withdrawn·UUniversity of Utah·Phase 1·NCT04315155

Multiple Myeloma2 trials

Study of Lenalidomide/Dexamethasone With Nivolumab and Ipilimumab in Patients With Newly Diagnosed Multiple Myeloma

Withdrawn·MM.D. Anderson Cancer Center·Phase 1·NCT03283046

An Investigational Immuno-Therapy Study to Determine the Safety and Effectiveness of Nivolumab and Daratumumab in Patients With Multiple Myeloma

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 1/2·NCT01592370·320 enrolled

Breast Cancer2 trials

NOvel Immunotherapy Strategies for Advanced Triple Negative Breast Cancer (TNBC) Patients: TONIC-3 Trial

Recruiting·TThe Netherlands Cancer Institute·Phase 2·NCT06342037·60 enrolled

Pre-operative Trial for Breast Cancer With Nivolumab in Combination With Novel IO

Recruiting·TThe Netherlands Cancer Institute·Phase 2·NCT03815890·80 enrolled

Pleural Mesothelioma2 trials

DuRvalumab With chEmotherapy as First Line treAtment in Advanced Pleural Mesothelioma

Completed·PPrECOG, LLC.·Phase 3·NCT04334759·214 enrolled

A Study to Evaluate Nivolumab in Combination With Ipilimumab Versus Pemetrexed With Cisplatin or Carboplatin for Unresectable Pleural Mesothelioma in Chinese Participants

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 2·NCT05136677·102 enrolled

Metastasis2 trials

A Study of Fotemustine(FTM) Vs FTM and Ipilimumab (IPI) or IPI and Nivolumab in Melanoma Brain Metastasis

Unknown status·IItalian Network for Tumor Biotherapy Foundation·Phase 3·NCT02460068·168 enrolled

Optune Device - TT Field Plus Nivolumab and Ipilimumab for Melanoma With Brain Metastasis

Terminated·WWashington University School of Medicine·Phase 2·NCT03903640·2 enrolled

Lung Cancer2 trials

Checkpoint Inhibitor Combinations Therapy as First Line for Inoperable Lung Cancer Via IT

Recruiting·SSecond Affiliated Hospital of Guangzhou Medical University·Phase 2·NCT06483347·90 enrolled

Neoadjuvant Intra-tumor Double Immunotherapy for Lung Cancer.

Recruiting·SSecond Affiliated Hospital of Guangzhou Medical University·Phase 2·NCT06492421·90 enrolled

Salivary Gland Cancer2 trials

Nivolumab and Ipilimumab in Treating Patients With Metastatic/Recurrent ACC of All Sites and Non-ACC Salivary Gland Cancer

Unknown status·NNorthwestern University·Phase 2·NCT03146650·25 enrolled

Study of Nivolumab Plus Ipilimumab in Patients With Salivary Gland Cancer

Completed·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT03172624·64 enrolled

Uveal Melanoma2 trials

CAVATAK® and Ipilimumab in Uveal Melanoma Metastatic to the Liver (VLA-024 CLEVER)

Completed·VViralytics·Phase 1·NCT03408587·11 enrolled

Radioembolization and Ipilimumab in Treating Patients With Uveal Melanoma With Liver Metastases

Terminated·—·Phase 1·NCT01730157·6 enrolled

Acute Myeloid Leukemia2 trials

Nivolumab and Azacitidine With or Without Ipilimumab in Treating Patients With Refractory/Relapsed or Newly Diagnosed Acute Myeloid Leukemia

Completed·MM.D. Anderson Cancer Center·Phase 2·NCT02397720·150 enrolled

A Vaccine (VSV-hIFNβ-NIS) With or Without Cyclophosphamide and Combinations of Ipilimumab, Nivolumab, and Cemiplimab in Treating Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia or Lymphoma

Recruiting·MMayo Clinic·Phase 1·NCT03017820·127 enrolled

Locally Advanced or Metastatic Solid Tumors2 trials

A Study to Assess the Safety and Tolerability of Atezolizumab in Combination With Other Immune-Modulating Therapies in Participants With Locally Advanced or Metastatic Solid Tumors

Completed· Roche logo

Roche·Phase 1·NCT02174172·158 enrolled

Study of SQZ-AAC-HPV in Patients With HPV16+ Recurrent, Locally Advanced or Metastatic Solid Tumors

Terminated·SSQZ Biotechnologies·Phase 1·NCT04892043·5 enrolled

Myelodysplastic Syndrome2 trials

Ipilimumab and Decitabine in Treating Patients With Relapsed or Refractory Myelodysplastic Syndrome or Acute Myeloid Leukemia

Active, not recruiting·NNational Cancer Institute (NCI)·Phase 1·NCT02890329·54 enrolled

Nivolumab and Ipilimumab After Donor Stem Cell Transplant in Treating Patients With High Risk Refractory or Relapsed Acute Myeloid Leukemia or Myelodysplastic Syndrome

Completed·MM.D. Anderson Cancer Center·Phase 1·NCT03600155·29 enrolled

Urothelial Carcinoma1 trial

First-Line Gemcitabine, Cisplatin + Ipilimumab for Metastatic Urothelial Carcinoma

Completed·HHoosier Cancer Research Network·Phase 2·NCT01524991·36 enrolled

Metastatic Prostate Cancer1 trial

Stereotactic Body Radiation Therapy With REGN2810 and/or Ipilimumab Before Surgery in Treating Participants With Progressive Advanced or Oligometastatic Prostate Cancer

Withdrawn·SSidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University·Phase 1·NCT03477864

Bladder Cancer1 trial

A Study to Test the Safety of Immunotherapy With Nivolumab Alone or With Ipilimumab Before Surgery for Bladder Cancer Patients Who Are Not Suitable for Chemotherapy

Active, not recruiting·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT03520491·52 enrolled

Safety and Efficacy1 trial

A Phase II Study to Evaluate Safety and Efficacy of Combined Treatment With Ipilimumab and Intratumoral Interleukin-2

Completed·UUniversity Hospital Tuebingen·Phase 2·NCT01480323·15 enrolled

Combination Therapy1 trial

A Study of Nivolumab Alone or Nivolumab Combination Therapy in Colon Cancer That Has Come Back or Has Spread

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 2·NCT02060188·385 enrolled

Cutaneous Melanoma1 trial

SUPRAME-ACTengine® IMA203 vs. Investigator's Choice of Treatment in Previously Treated, Unresectable or Metastatic Cutaneous Melanoma

Recruiting·IImmatics US, Inc.·Phase 3·NCT06743126·360 enrolled

Metastatic Renal Cell Cancer1 trial

A Study to Evaluate the Safety of Nivolumab and Ipilimumab in Subjects With Previously Untreated Advanced or Metastatic Renal Cell Cancer

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 4·NCT02982954·211 enrolled

Fibrolamellar Carcinoma1 trial

A DNAJB1-PRKACA Fusion Kinase Peptide Vaccine Combined With Glutamine Antagonist DRP-104, Nivolumab, and Ipilimumab in Patients With Advanced Stage Fibrolamellar Carcinoma (FLC)

Not yet recruiting·SSidney Kimmel Comprehensive Cancer Center at Johns Hopkins·Phase 1·NCT07430202·27 enrolled

Pancreatic Adenocarcinoma1 trial

Maintenance Niraparib Plus Ipilimumab in Patients With Metastatic Pancreatic Adenocarcinoma Whose Disease Has Not Progressed on Platinum-Based Chemotherapy

Recruiting·—·Phase 2·NCT06747845·68 enrolled

Intratumoral Injection1 trial

A Phase I/II Study of Intratumoral Injection of SD-101

Completed·RRobert Lowsky·Phase 1/2·NCT02254772·9 enrolled

Advanced or Metastatic Solid Tumors1 trial

A Study of Nivolumab by Itself or Nivolumab Combined With Ipilimumab in Patients With Advanced or Metastatic Solid Tumors

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 1/2·NCT01928394·1,163 enrolled

Soft Tissue Sarcoma1 trial

Ipilimumab + Nivolumab + Cryotherapy in Metastatic or Locally Advanced Soft Tissue Sarcoma

Completed·KKristen Ganjoo·Phase 2·NCT04118166·30 enrolled

Metastatic NSCLC1 trial

Real-World Comparison of Chemo-Immunotherapy Regimens in Metastatic NSCLC With PD-L1 <50% (ALCG-01)

Recruiting·GGazi University··NCT07394062·400 enrolled

Neoadjuvant1 trial

Neo IRENIE (NEOadjuvant Ipilimumab, RElatlimab, NIvolumab Evaluation)

Recruiting·MMelanoma Institute Australia·Phase 2·NCT06999980·494 enrolled

Budesonide1 trial

A Study of MDX-010 (BMS-734016) Administered With or Without Prophylactic Oral Budesonide

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 2·NCT00135408·115 enrolled

HCC1 trial

Checkpoint Inhibitor Combinations Therapy as First Line for HCC Via IT

Recruiting·SSecond Affiliated Hospital of Guangzhou Medical University·Phase 2·NCT06482801·90 enrolled

Neuroendocrine Carcinoma1 trial

NP-101 (TQ Formula) With Nivolumab and Ipilimumab in Advanced or Metastatic Extra-pulmonary Neuroendocrine Carcinomas

Active, not recruiting·—·Phase 1·NCT05262556·15 enrolled

Trial1 trial

The Drug Rediscovery Protocol (DRUP Trial)

Recruiting·TThe Netherlands Cancer Institute·Phase 2·NCT02925234·1,550 enrolled

Immune System1 trial

Study of Ipilimumab in the Immune System

Completed·UUniversity Health Network, Toronto·N/A·NCT01715077·4 enrolled

Solid Tumors1 trial

Ph I/II Trial of Systemic VSV-IFNβ-NIS in Combination With Checkpoint Inhibitor Therapy in Patients With Select Solid Tumors

Active, not recruiting·VVyriad, Inc.·Phase 1/2·NCT03647163·33 enrolled

Chemoradiotherapy1 trial

Checkpoint Inhibition and Chemoradiotherapy as Bladder Sparing Treatment in UC

Active, not recruiting·TThe Netherlands Cancer Institute·Phase 2·NCT05200988·50 enrolled

Colorectal Cancer1 trial

Neoadjuvant Immunotherapy ± Radiotherapy in MSI-H/dMMR Locally Advanced Colorectal Cancer

Not yet recruiting·FFudan University·Phase 2·NCT07403877·114 enrolled

Cytoreductive Nephrectomy1 trial

Immediate Versus Deferred Cytoreductive Nephrectomy With Ipilimumab/Nivolumab in mRCC

Not yet recruiting·SSeoul National University Hospital·N/A·NCT07233668·172 enrolled

Hepatocellular Cancer1 trial

Ipilimumab and Nivolumab With SBRT in Locally Advanced Hepatocellular Cancer

Not yet recruiting·UUniversity of Hawaii·Phase 1·NCT07075120·15 enrolled

Randomized1 trial

Randomized Phase-II Study of Nivolumab Plus Ipilimumab vs. Standard of Care in Untreated and Advanced Non-clear Cell RCC

Completed·GGoethe University·Phase 2·NCT03075423·316 enrolled

Brain Tumors1 trial

Improved Therapy Response Assessment in Metastatic Brain Tumors

Unknown status·OOslo University Hospital··NCT03458455·200 enrolled

Cervical Cancer1 trial

Nivolumab-ipilimumab and Chemoradiation for Cervical Cancer

Recruiting·HHospital Israelita Albert Einstein·Phase 2·NCT05492123·112 enrolled

Gastric Adenocarcinoma1 trial

Pre-operative Nivolumab and Ipilimumab, Followed by Post-operative Nivolumab, for MSI/dMMR Oeso-gastric Adenocarcinoma.

Active, not recruiting·GGERCOR - Multidisciplinary Oncology Cooperative Group·Phase 2·NCT04006262·32 enrolled

Dendritic Cell1 trial

Clinical Trial of SBRT and Systemic Pembrolizumab With or Without Avelumab/Ipilimumab+ Dendritic Cells in Solid Tumors

Unknown status·UUniversitair Ziekenhuis Brussel·Phase 2·NCT04571632·36 enrolled

Stem Cell Transplant1 trial

Ipilimumab After Allogeneic Stem Cell Transplant in Treating Patients With Persistent or Progressive Cancer

Completed·NNational Cancer Institute (NCI)·Phase 1·NCT00060372·21 enrolled

Refractory Cancer1 trial

Recombinant Interleukin-15 in Combination With Checkpoint Inhibitors Nivolumab and Ipilimumab in People With Refractory Cancers

Completed·NNational Cancer Institute (NCI)·Phase 1·NCT03388632·31 enrolled

Advanced Cancer1 trial

Ipilimumab and Lenalidomide in Advanced Cancer

Completed·MM.D. Anderson Cancer Center·Phase 1·NCT01750983·101 enrolled

Head and Neck Squamous Cell Carcinoma1 trial

Adjuvant Immunotherapy After Salvage Surgery in Head and Neck Squamous Cell Carcinoma

Recruiting·GGustave Roussy, Cancer Campus, Grand Paris·Phase 2·NCT03406247·140 enrolled

Ovarian Cancer1 trial

A Study of Carboplatin and Paclitaxel Chemotherapy With Nivolumab With or Without Ipilimumab in Patients With Ovarian Cancer

Completed·MMemorial Sloan Kettering Cancer Center·Phase 1·NCT03245892·27 enrolled

Metastatic Cancer1 trial

Immunotherapy in Patients With Metastatic Cancers and CDK12 Mutations

Completed·UUniversity of Michigan Rogel Cancer Center·Phase 2·NCT03570619·56 enrolled

Active, not recruiting·HHatim Husain·Phase 1/2·NCT04043195·30 enrolled

Efficacy and Safety1 trial

A Study to Investigate the Efficacy and Safety of Volrustomig ± Casdatifan vs Nivolumab + Ipilimumab as 1L Treatment for Advanced ccRCC

Active, not recruiting· AstraZeneca logo

AstraZeneca·Phase 3·NCT07000149·1,116 enrolled

Renal Cell Cancer1 trial

Advanced Renal Cell Cancer Combination ImmunoThErapy Clinical Trial

Suspended·MMichael B. Atkins, MD·Phase 2·NCT05928806·120 enrolled

Gastrointestinal Stromal Tumor1 trial

Dasatinib and Ipilimumab in Treating Patients With Gastrointestinal Stromal Tumors or Other Sarcomas That Cannot Be Removed by Surgery or Are Metastatic

Completed·NNational Cancer Institute (NCI)·Phase 1·NCT01643278·29 enrolled

Pediatric Solid Tumors1 trial

Neoadjuvant Dual Checkpoint Inhibition and Cryoablation in Relapsed/Refractory Pediatric Solid Tumors

Completed·—·Phase 2·NCT05302921·5 enrolled

Ocular Melanoma1 trial

Study of Adjuvant Ipilimumab and Nivolumab in Subjects With High-risk Ocular Melanoma

Unknown status·SSuthee Rapisuwon·Phase 2·NCT03528408·52 enrolled

Head and Neck Cancer1 trial

VX15/2503 in Combination With Ipilimumab or Nivolumab in Patients With Head and Neck Cancer

Recruiting·EEmory University·Phase 1·NCT03690986·50 enrolled

Chronic Lymphocytic Leukemia1 trial

Ipilimumab, Ibrutinib, and Nivolumab for the Treatment of Chronic Lymphocytic Leukemia and Richter Transformation

Withdrawn·MM.D. Anderson Cancer Center·Phase 1·NCT04781855

Biomarkers1 trial

Biomarkers of Response to Ipilimumab and Nivolumab in First-line NSCLC

Terminated·—·Phase 2·NCT03425331·5 enrolled

Resectable NSCLC1 trial

Neoadjuvant Nivolumab, or Nivolumab in Combination With Ipilimumab, in Resectable NSCLC

Active, not recruiting·SSidney Kimmel Comprehensive Cancer Center at Johns Hopkins·Phase 2·NCT02259621·39 enrolled

Thyroid Cancer1 trial

Nivolumab Plus Ipilimumab in Thyroid Cancer

Completed·—·Phase 2·NCT03246958·53 enrolled

Leukemia1 trial

Blinatumomab and Nivolumab With or Without Ipilimumab in Treating Patients With Poor-Risk Relapsed or Refractory CD19+ Precursor B-Lymphoblastic Leukemia

Active, not recruiting·NNational Cancer Institute (NCI)·Phase 1·NCT02879695·28 enrolled

Metastatic Sarcoma1 trial

Nivolumab With or Without Ipilimumab in Treating Patients With Metastatic Sarcoma That Cannot Be Removed by Surgery

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT02500797·164 enrolled

Locally Advanced1 trial

Inulin Gel in Combination With Ipilimumab and Nivolumab for the Treatment of Metastatic or Locally Advanced Kidney Cell Cancer, ICON Trial

Recruiting·UUniversity of Michigan Rogel Cancer Center·Phase 1/2·NCT06866262·55 enrolled

Squamous Cell Carcinoma1 trial

Study of Nivolumab in Combination With Ipilimumab Compared to the Standard of Care (Extreme Regimen) as First Line Treatment in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 3·NCT02741570·947 enrolled

Patients With Advanced Solid Tumors1 trial

MAQ-001 in Patients With Advanced Solid Tumors

Recruiting·MMabQuest SA·Phase 1·NCT06514651·30 enrolled

Pituitary Tumor1 trial

Nivolumab and Ipilimumab in People With Aggressive Pituitary Tumors

Active, not recruiting·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT04042753·9 enrolled

Malignancies1 trial

Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies

Completed·IIncyte Biosciences International Sàrl·Phase 1/2·NCT03126110·145 enrolled

Metastatic Urothelial Cancer1 trial

Study of NIVOLUMAB/IPILIMUMAB Maintenance in Unresectable Locally Advanced or Metastatic Urothelial Cancer

Active, not recruiting·SSpanish Oncology Genito-Urinary Group·Phase 2·NCT05219435·66 enrolled

Synovial Sarcoma1 trial

A Study of Anti-CTLA-4 Antibody in Patients With Advanced Synovial Sarcoma

Terminated·LLudwig Institute for Cancer Research·Phase 2·NCT00140855·6 enrolled

Small Cell Lung Carcinoma1 trial

Small Cell Lung Carcinoma Trial With Nivolumab and IpiliMUmab in LImited Disease

Completed·EETOP IBCSG Partners Foundation·Phase 2·NCT02046733·222 enrolled

Tumors1 trial

Pressure Enabled Delivery of SD-101 With Checkpoint Blockade for Primary Liver Tumors

Terminated·TTriSalus Life Sciences, Inc.·Phase 1/2·NCT05220722·23 enrolled

Undifferentiated Pleomorphic Sarcoma1 trial

ENVASARC: Envafolimab And Envafolimab With Ipilimumab In Patients With Undifferentiated Pleomorphic Sarcoma Or Myxofibrosarcoma

Active, not recruiting·TTracon Pharmaceuticals Inc.·Phase 2·NCT04480502·207 enrolled

Advanced or Recurrent Solid Tumors1 trial

A Study of Nivolumab in Combination With Ipilimumab in Chinese Participants With Previously Treated Advanced or Recurrent Solid Tumors

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 1/2·NCT03195478·37 enrolled

Phase II Clinical Trial1 trial

Phase II Clinical Trial of NIVO-IPI-TAXANE in Untreated Metastatic NSCLC

Completed·JJeffrey Clarke·Phase 2·NCT03573947·46 enrolled

Liver Cancer1 trial

Nivolumab With or Without Ipilimumab in Treating Patients With Resectable Liver Cancer

Completed·MM.D. Anderson Cancer Center·Phase 2·NCT03222076·30 enrolled

Metastatic Solid Tumors1 trial

Glembatumumab Vedotin, Nivolumab, and Ipilimumab in Treating Patients With Advanced Metastatic Solid Tumors That Cannot Be Removed by Surgery

Withdrawn·NNational Cancer Institute (NCI)·Phase 1/2·NCT03326258

Regulatory

FDA Approval Timeline[4]

Mar 25, 2011

YERVOY

BLA BLA125377

Sources

References

[1]
ClinicalTrials.gov — 700 trial records for Ipilimumab. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Ipilimumab compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Ipilimumab. EMBL-EBI & Wellcome Sanger Institute.
[4]
OpenFDA — FDA approval records (BLA BLA125377). U.S. Food & Drug Administration.
[5]
SEC EDGAR — Bristol-Myers Squibb company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Mechanism of Action: Cytotoxic T-Lymphocyte Protein 4 Inhibitor[2]
Modality: Monoclonal antibody[2]
Highest Phase: Phase 3[1]
Company: Bristol-Myers Squibb

Yervoy

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2026

Trials by Indication[1]

Melanoma31 trials

Metastatic Melanoma17 trials

Non-Small Cell Lung Cancer7 trials

Immunotherapy6 trials

Renal Cell Carcinoma5 trials

Pancreatic Cancer5 trials

Prostate Cancer5 trials

Glioblastoma5 trials

Lymphoma5 trials

Gastric Cancer4 trials

Nivolumab4 trials

Metastatic Colorectal Cancer4 trials

Small Cell Lung Cancer3 trials

Hepatocellular Carcinoma3 trials

Advanced Solid Tumors3 trials

Kidney Cancer3 trials

Merkel Cell Carcinoma2 trials

Patients With Solid Tumors2 trials

Metastatic2 trials

Multiple Myeloma2 trials

Breast Cancer2 trials

Pleural Mesothelioma2 trials

Metastasis2 trials

Lung Cancer2 trials

Salivary Gland Cancer2 trials

Uveal Melanoma2 trials

Acute Myeloid Leukemia2 trials

Locally Advanced or Metastatic Solid Tumors2 trials

Myelodysplastic Syndrome2 trials

Urothelial Carcinoma1 trial

Metastatic Prostate Cancer1 trial

Bladder Cancer1 trial

Safety and Efficacy1 trial

Combination Therapy1 trial

Cutaneous Melanoma1 trial

Metastatic Renal Cell Cancer1 trial

Fibrolamellar Carcinoma1 trial

Pancreatic Adenocarcinoma1 trial

Intratumoral Injection1 trial

Advanced or Metastatic Solid Tumors1 trial

Soft Tissue Sarcoma1 trial

Metastatic NSCLC1 trial

Neoadjuvant1 trial

Budesonide1 trial

HCC1 trial

Neuroendocrine Carcinoma1 trial

Trial1 trial

Immune System1 trial

Solid Tumors1 trial

Chemoradiotherapy1 trial

Colorectal Cancer1 trial

Cytoreductive Nephrectomy1 trial

Hepatocellular Cancer1 trial

Randomized1 trial

Brain Tumors1 trial

Cervical Cancer1 trial

Gastric Adenocarcinoma1 trial

Dendritic Cell1 trial

Stem Cell Transplant1 trial

Refractory Cancer1 trial

Advanced Cancer1 trial

Head and Neck Squamous Cell Carcinoma1 trial

Ovarian Cancer1 trial

Metastatic Cancer1 trial

Carcinosarcoma1 trial

Chemoradiation1 trial

Advanced NSCLC1 trial

Efficacy and Safety1 trial

Renal Cell Cancer1 trial

Gastrointestinal Stromal Tumor1 trial

Pediatric Solid Tumors1 trial

Ocular Melanoma1 trial

Head and Neck Cancer1 trial

Chronic Lymphocytic Leukemia1 trial